D Keizman

Summary

Publications

  1. ncbi request reprint [Metastatic hormone refractory prostate cancer: new treatment horizon]
    Daniel Keizman
    Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler Faculty of Medicine, Tel Aviv University
    Harefuah 151:545-9, 555, 554. 2012
  2. doi request reprint Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?
    Daniel Keizman
    Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Tchernichovsky 59, 44281, Kfar Saba, Israel
    World J Urol 32:39-45. 2014
  3. pmc Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram
    Daniel Keizman
    Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel
    Oncologist 17:1508-14. 2012
  4. doi request reprint Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma
    Daniel Keizman
    Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Israel
    Eur J Cancer 48:1031-7. 2012
  5. pmc The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Eur J Cancer 48:202-8. 2012
  6. pmc Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Prostate 72:461-7. 2012
  7. pmc Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Eur J Cancer 47:1955-61. 2011
  8. pmc Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 16:5269-76. 2010
  9. doi request reprint An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate
    Daniel Keizman
    Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Cancer 116:251-5. 2010
  10. doi request reprint Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis
    D Keizman
    Department of Oncology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Acta Neurol Scand 119:383-9. 2009

Detail Information

Publications12

  1. ncbi request reprint [Metastatic hormone refractory prostate cancer: new treatment horizon]
    Daniel Keizman
    Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler Faculty of Medicine, Tel Aviv University
    Harefuah 151:545-9, 555, 554. 2012
    ..This review will focus on recent advances in the standard treatments paradigm in mHRPC...
  2. doi request reprint Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?
    Daniel Keizman
    Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Tchernichovsky 59, 44281, Kfar Saba, Israel
    World J Urol 32:39-45. 2014
    ..Data suggest that they may also improve the outcome of systemic targeted therapies. Herein we review the preclinical and clinical data on their use, as well as remaining open questions. ..
  3. pmc Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram
    Daniel Keizman
    Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel
    Oncologist 17:1508-14. 2012
    ..We assessed the association between the pretreatment NLR and outcome of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the CYP17 inhibitor ketoconazole...
  4. doi request reprint Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma
    Daniel Keizman
    Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Israel
    Eur J Cancer 48:1031-7. 2012
    ....
  5. pmc The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Eur J Cancer 48:202-8. 2012
    ..Sunitinib is a standard treatment for metastatic renal cell carcinoma (mRCC). The neutrophil to lymphocyte ratio (NLR), an index of systemic inflammation, is associated with outcome in several cancer types...
  6. pmc Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Prostate 72:461-7. 2012
    ....
  7. pmc Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Eur J Cancer 47:1955-61. 2011
    ..Data suggests that they may inhibit tumourigenesis...
  8. pmc Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 16:5269-76. 2010
    ..To evaluate the safety and activity of 6 months of treatment with lenalidomide at 5 or 25 mg/d in nonmetastatic biochemically relapsed prostate cancer...
  9. doi request reprint An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate
    Daniel Keizman
    Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Cancer 116:251-5. 2010
    ..The current study was designed to establish an animal model of CASH and to use that model to study the effect of FABACs on its occurrence...
  10. doi request reprint Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis
    D Keizman
    Department of Oncology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Acta Neurol Scand 119:383-9. 2009
    ..To prospectively determine the intensity of systemic low-grade inflammation in patients with amyotrophic lateral sclerosis (ALS)...
  11. doi request reprint Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress?
    D Keizman
    Department of Internal Medicine H, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    J Neurol Sci 285:95-9. 2009
    ..The objective of this study was to prospectively determine the serum uric acid levels in ALS patients and allegedly healthy individuals and to correlate those values with measures of ALS disease progression among the patients...
  12. ncbi request reprint The clinical significance of bile duct sludge: is it different from bile duct stones?
    D Keizman
    Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Surg Endosc 21:769-73. 2007
    ..This study aimed to compare BDS with bile duct stones in terms of frequency, associated risk factors, and clinical outcome after endoscopic therapy...